<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609241</url>
  </required_header>
  <id_info>
    <org_study_id>CD79b-001</org_study_id>
    <nct_id>NCT04609241</nct_id>
  </id_info>
  <brief_title>CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Clinical Trial for the Safety and Efficacy of Murine CD79b CAR-T Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yake Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute&#xD;
      Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open-label, single-center study. This study is indicated for relapsed&#xD;
      or refractory Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell&#xD;
      Non-Hodgkin's Lymphoma. The selections of dose levels and the number of subjects are based on&#xD;
      clinical trials of similar foreign products. 72 patients will be enrolled. Primary objective&#xD;
      is to explore the safety, main consideration is dose-related safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2020</start_date>
  <completion_date type="Anticipated">November 15, 2026</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days after CD79b targeted CAR T-cells infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 2 years after CD79b targeted CAR T-cells infusion</time_frame>
    <description>Incidence of treatment-emergent adverse events [Safety and Tolerability]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Lymphoblastic Leukemia (ALL), Overall response rate (ORR)</measure>
    <time_frame>At Month 1, 3, 6, 12, 18 and 24</time_frame>
    <description>Assessment of ORR (ORR = CR + CRi) at Month 6, 12, 18 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALL, Overall survival（OS）</measure>
    <time_frame>Up to 2 years after CD79b CAR-T cells infusion</time_frame>
    <description>From the first infusion of CD79b CAR-T cells to death or the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALL, Event-free survival (EFS)</measure>
    <time_frame>Up to 2 years after CD79b CAR-T cells infusion</time_frame>
    <description>From the first infusion of CD79b CAR-T cells to the occurrence of any event, including death, relapse or generelapse, disease progression (any one occurs first), and the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell Non-Hodgkin's Lymphoma（B-NHL）, Overall response rate (ORR)</measure>
    <time_frame>At Month 1, 3, 6, 12, 18 and 24</time_frame>
    <description>Assessment of ORR (ORR = CR + CRi) at Month 6, 12, 18 and 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-NHL, Overall survival（OS）</measure>
    <time_frame>Up to 2 years after CD79b CAR-T cells infusion</time_frame>
    <description>From the first infusion of CD79b CAR-T cells to death or the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-NHL, Event-free survival (EFS)</measure>
    <time_frame>Up to 2 years after CD79b CAR-T cells infusion</time_frame>
    <description>From the first infusion of CD79b CAR-T cells to the occurrence of any event, including death, relapse or generelapse, disease progression (any one occurs first), and the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(EORTC QLQ-C30) Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>At Baseline, Month 1, 3, 6, 9 and 12</time_frame>
    <description>Assessment using European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scale [For item1-28: max score: 112, min score: 28, higher scores mean a better outcome; for item 28-29: max score: 14, min score: 2, higher scores mean a worse outcome] to measure Quality of life at Baseline, Month 1, 3, 6, 9 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living (ADL) score</measure>
    <time_frame>At Baseline, Month 1, 3, 6, 9 and 12</time_frame>
    <description>Assessment using Activities of Daily Living (ADL) scale (Barthel Index) [max score: 100, min score: 0, higher scores mean a better outcome] at Baseline, Month 1, 3, 6, 9 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instrumental Activities of Daily Living (IADL) score</measure>
    <time_frame>At Baseline, Month 1, 3, 6, 9 and 12</time_frame>
    <description>Assessment of Instrumental Activities of Daily Living (IADL) scale [max score: 56, min score: 14, higher scores mean a worse outcome] at Baseline, Month 1, 3, 6, 9 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale (HADS) score</measure>
    <time_frame>At Baseline, Month 1, 3, 6, 9 and 12</time_frame>
    <description>Assessment using Hospital Anxiety and Depression Scale (HADS) [max score: 42, min score: 0, higher scores mean a worse outcome] at Baseline, Month 1, 3, 6, 9 and 12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Relapsed and/or Refractory Acute Lymphoblastic Leukemia</condition>
  <condition>Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Administration of CD79b CAR-T Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD79b CAR-T Cells</intervention_name>
    <description>Each subject receive CD79b CAR-Tcells by intravenous infusion</description>
    <arm_group_label>Administration of CD79b CAR-T Cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Only For B-ALL&#xD;
&#xD;
               1. No gender or age limit&#xD;
&#xD;
               2. Histologically confirmed diagnosis of CD69b+ B-ALL per the US National&#xD;
                  Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute&#xD;
                  Myeloid Leukemia (2016.v1);&#xD;
&#xD;
               3. Relapsed or refractory CD123+ AML (meeting one of the following conditions):&#xD;
&#xD;
                    1. CR not achieved after standardized chemotherapy;&#xD;
&#xD;
                    2. CR achieved following the first induction, but CR duration is less than 12&#xD;
                       months;&#xD;
&#xD;
                    3. Ineffectively after first or multiple remedial treatments;&#xD;
&#xD;
                    4. 2 or more relapses;&#xD;
&#xD;
               4. The number of primordial cells in bone marrow is &gt; 5% (by morphology), and/or &gt;&#xD;
                  0.01% (by flowcytometry);&#xD;
&#xD;
               5. Philadelphia chromosome negative(Ph-) subjects; Ph+ subjects who cannot tolerate&#xD;
                  tyrosine kinase inhibitor (TKI) treatment or who do not respond to two kinds of&#xD;
                  TKI treatment;&#xD;
&#xD;
          -  Only For B-NHL&#xD;
&#xD;
               1. No gender or age limit;&#xD;
&#xD;
               2. Histologically confirmed diagnosis of DLBCL (NOS), FL, DLBCL transformed from&#xD;
                  CLL/SLL, PMBCL, and HGBCL per the WHO Classification Criteria for Lymphoma&#xD;
                  (2016);&#xD;
&#xD;
               3. Relapsed or refractory B-NHL (meeting one of the following conditions):&#xD;
&#xD;
               1. No response or relapse after second-line or above chemotherapy regimens;&#xD;
&#xD;
               2. Primary drug resistance;&#xD;
&#xD;
               3. Relapse after auto-HSCT;&#xD;
&#xD;
               4. At least one assessable tumor lesion per Lugano 2014 criteria&#xD;
&#xD;
          -  For both B-ALL and B-NHL&#xD;
&#xD;
               1. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal,&#xD;
                  creatinine ≤ 176.8 umol/L;&#xD;
&#xD;
               2. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;&#xD;
&#xD;
               3. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;&#xD;
&#xD;
               4. Estimated survival time ≥ 3 months;&#xD;
&#xD;
               5. ECOG performance status 0 to 2;&#xD;
&#xD;
               6. Patients or their legal guardians volunteer to participate in the studyand sign&#xD;
                  the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular&#xD;
             ischemia, and cerebrovascular, hemorrhagicdiseases; 2. Electrocardiogram shows&#xD;
             prolonged QT interval, severe heart diseasessuch as severe arrhythmia in the past; 3.&#xD;
             Pregnant (or lactating) women; 4. Patients with severe active infections (excluding&#xD;
             simple urinarytractinfectionand bacterial pharyngitis); 5. Active infection of&#xD;
             hepatitis B virus or hepatitis C virus; 6. Previously treated with any CAR-T cell&#xD;
             product or other genetically modified T cell therapies; 7. Insufficient amplification&#xD;
             capacity in response to CD3 / CD28 co-stimulus signal (&lt;5 times) 8.&#xD;
             Creatinine&gt;2.5mg/dl, or ALT / AST &gt; 3 times of normal amounts, or bilirubin&gt;2.0 mg/dl;&#xD;
             9. Other uncontrolled diseases that were not suitable for this trial; 10. Patients&#xD;
             with HIV infection; 11. Any situations that the investigator believes may increase the&#xD;
             risk ofpatients or interfere with the results of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>He Huang, PhD</last_name>
    <phone>86-13605714822</phone>
    <email>huangheyu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongxian Hu, PhD</last_name>
    <phone>86-15957162012</phone>
    <email>huyongxian2000@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>He Huang, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

